{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T09:37:22Z","timestamp":1794908242996,"version":"4.9.1"},"reference-count":144,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T00:00:00Z","timestamp":1745020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T00:00:00Z","timestamp":1745020800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21877113"],"award-info":[{"award-number":["21877113"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21877113"],"award-info":[{"award-number":["21877113"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173744"],"award-info":[{"award-number":["82173744"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"crossref","award":["2024Y0051"],"award-info":[{"award-number":["2024Y0051"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Key Research and Development Program of China","award":["2022YFB3503700"],"award-info":[{"award-number":["2022YFB3503700"]}]},{"name":"Self-deployment Project Research Program of Haixi Institutes, Chinese Academy of Sciences","award":["CXZX-2022-GH10"],"award-info":[{"award-number":["CXZX-2022-GH10"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-025-02253-6","type":"journal-article","created":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T06:19:22Z","timestamp":1745043562000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Transient intracellular expression of PD-L1 and VEGFR2 bispecific nanobody in cancer cells inspires long-term T cell activation and infiltration to combat tumor and inhibit cancer metastasis"],"prefix":"10.1186","volume":"24","author":[{"given":"Lei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfeng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaohua","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Shangguan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuzhi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jincan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe-Sheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zun-Fu","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,19]]},"reference":[{"key":"2253_CR1","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.apsb.2022.10.002","volume":"13","author":"L Zhang","year":"2023","unstructured":"Zhang L, Ye B, Chen Z, Chen Z-S. Progress in the studies on the molecular mechanisms associated with multidrug resistance in cancers. Acta Pharm Sin B. 2023;13:982\u201397.","journal-title":"Acta Pharm Sin B"},{"key":"2253_CR2","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1146\/annurev.med.53.082901.103929","volume":"53","author":"MM Gottesman","year":"2002","unstructured":"Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med. 2002;53:615\u201327.","journal-title":"Annu Rev Med"},{"key":"2253_CR3","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/nrc3599","volume":"13","author":"C Holohan","year":"2013","unstructured":"Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13:714\u201326.","journal-title":"Nat Rev Cancer"},{"key":"2253_CR4","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/ni.2035","volume":"12","author":"EJ Wherry","year":"2011","unstructured":"Wherry EJ. T cell exhaustion. Nat Immunol. 2011;12:492\u20139.","journal-title":"Nat Immunol"},{"key":"2253_CR5","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.cell.2015.10.054","volume":"163","author":"KE Pauken","year":"2015","unstructured":"Pauken KE, Wherry EJ. SnapShot: T Cell Exhaustion. Cell. 2015;163:1038-U299.","journal-title":"Cell"},{"key":"2253_CR6","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15:486\u201399.","journal-title":"Nat Rev Immunol"},{"key":"2253_CR7","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/s41590-024-01820-1","volume":"25","author":"ML Stone","year":"2024","unstructured":"Stone ML, Lee J, Lee JW, Coho H, Tariveranmoshabad M, Wattenberg MM, et al. Hepatocytes coordinate immune evasion in cancer via release of serum amyloid A proteins. Nat Immunol. 2024;25:755\u201363.","journal-title":"Nat Immunol"},{"key":"2253_CR8","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","volume":"348","author":"P Sharma","year":"2015","unstructured":"Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348:56\u201361.","journal-title":"Science"},{"key":"2253_CR9","doi-asserted-by":"publisher","first-page":"6742","DOI":"10.1038\/s41467-021-27078-x","volume":"12","author":"HP Fang","year":"2021","unstructured":"Fang HP, Guo ZP, Chen J, Lin L, Hu YY, Li YH, et al. Combination of epigenetic regulation with gene therapy-mediated immune checkpoint blockade induces anti-tumour effects and immune response in vivo. Nat Commun. 2021;12:6742.","journal-title":"Nat Commun"},{"key":"2253_CR10","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1038\/s43018-024-00772-7","volume":"5","author":"TG Chang","year":"2024","unstructured":"Chang TG, Cao YY, Sfreddo HJ, Dhruba SR, Lee SH, Valero C, et al. LORIS robustly predicts patient outcomes with immune checkpoint blockade therapy using common clinical, pathologic and genomic features. Nat Cancer. 2024;5:1158\u201375.","journal-title":"Nat Cancer"},{"key":"2253_CR11","doi-asserted-by":"publisher","first-page":"15057","DOI":"10.1038\/s41598-021-94336-9","volume":"11","author":"R Matsukane","year":"2021","unstructured":"Matsukane R, Watanabe H, Hata K, Suetsugu K, Tsuji T, Egashira N, et al. Prognostic significance of pre-treatment ALBI grade in advanced non-small cell lung cancer receiving immune checkpoint therapy. Sci Rep. 2021;11:15057.","journal-title":"Sci Rep"},{"key":"2253_CR12","doi-asserted-by":"publisher","first-page":"5151","DOI":"10.1038\/s41467-022-32838-4","volume":"13","author":"A Patterson","year":"2022","unstructured":"Patterson A, Auslander N. Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma. Nat Commun. 2022;13:5151.","journal-title":"Nat Commun"},{"key":"2253_CR13","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1038\/s41467-023-37568-9","volume":"14","author":"AG Robertson","year":"2023","unstructured":"Robertson AG, Meghani K, Cooley LF, McLaughlin KA, Fall LA, Yu YN, et al. Expression-based subtypes define pathologic response to neoadjuvant immune-checkpoint inhibitors in muscle-invasive bladder cancer. Nat Commun. 2023;14:2126.","journal-title":"Nat Commun"},{"key":"2253_CR14","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41591-021-01623-z","volume":"28","author":"AX Lozano","year":"2022","unstructured":"Lozano AX, Chaudhuri AA, Nene A, Bacchiocchi A, Earland N, Vesely MD, et al. T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma. Nat Med. 2022;28:353\u201362.","journal-title":"Nat Med"},{"key":"2253_CR15","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1038\/s43018-024-00729-w","volume":"5","author":"ETR Torres","year":"2024","unstructured":"Torres ETR, Ho WJ, Danilova L, Tandurella JA, Leatherman J, Rafie C, et al. Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial. Nat Cancer. 2024;5:866\u201379.","journal-title":"Nat Cancer"},{"key":"2253_CR16","doi-asserted-by":"publisher","first-page":"531","DOI":"10.2217\/imt-2022-0201","volume":"15","author":"PLSU Uson","year":"2023","unstructured":"Uson PLSU, Bekaii-Saab T. Moving beyond single-agent checkpoint inhibition in biliary tract cancers: what is the next frontier? Immunotherapy. 2023;15:531\u201340.","journal-title":"Immunotherapy"},{"key":"2253_CR17","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s00262-023-03623-z","volume":"73","author":"JF Hilton","year":"2024","unstructured":"Hilton JF, Ott PA, Hansen AR, Li ZJ, Mathew M, Messina CH, et al. INDUCE-2: A Phase I\/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors. Cancer Immunol Immun. 2024;73:44.","journal-title":"Cancer Immunol Immun"},{"key":"2253_CR18","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/s41591-024-02894-y","volume":"30","author":"M Yarchoan","year":"2024","unstructured":"Yarchoan M, Gane EJ, Marron TU, Perales-Linares R, Yan J, Cooch N, et al. Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1\/2 trial. Nat Med. 2024;30:1044\u201353.","journal-title":"Nat Med"},{"key":"2253_CR19","doi-asserted-by":"publisher","first-page":"784","DOI":"10.3389\/fimmu.2020.00784","volume":"11","author":"F Petitprez","year":"2020","unstructured":"Petitprez F, Meylan M, de Reyni\u00e8s A, Saut\u00e8s-Fridman C, Fridman WH. The tumor microenvironment in the response to immune checkpoint blockade therapies. Front Immunol. 2020;11:784.","journal-title":"Front Immunol"},{"key":"2253_CR20","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1038\/s41591-024-03007-5","volume":"30","author":"XY Gao","year":"2024","unstructured":"Gao XY, Ji K, Jia YN, Shan F, Chen Y, Xu N, et al. Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b\/2 COMPASSION-04 trial. Nat Med. 2024;30:1943\u201351.","journal-title":"Nat Med"},{"key":"2253_CR21","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1038\/s41467-023-37030-w","volume":"14","author":"TM Zeng","year":"2023","unstructured":"Zeng TM, Yang G, Lou C, Wei W, Tao CJ, Chen XY, et al. Clinical and biomarker analyses of sintilimab plus gemcitabine and cisplatin as first-line treatment for patients with advanced biliary tract cancer. Nat Commun. 2023;14:1340.","journal-title":"Nat Commun"},{"key":"2253_CR22","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/j.1476-5381.2009.00190.x","volume":"157","author":"P Chames","year":"2009","unstructured":"Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol. 2009;157:220\u201333.","journal-title":"Br J Pharmacol"},{"key":"2253_CR23","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1093\/intimm\/8.5.765","volume":"8","author":"Y Agata","year":"1996","unstructured":"Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol. 1996;8:765\u201372.","journal-title":"Int Immunol"},{"key":"2253_CR24","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir ME, Butte MJ, Freeman GJ, Sharpel AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677\u2013704.","journal-title":"Annu Rev Immunol"},{"key":"2253_CR25","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1093\/intimm\/8.5.773","volume":"8","author":"H Nishimura","year":"1996","unstructured":"Nishimura H, Agata Y, Kawasaki A, Sato M, Imamura S, Minato N, et al. Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes. Int Immunol. 1996;8:773\u201380.","journal-title":"Int Immunol"},{"key":"2253_CR26","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/70932","volume":"5","author":"H Dong","year":"1999","unstructured":"Dong H, Zhu G, Tamada K, Chen L. B7\u2013H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999;5:1365\u20139.","journal-title":"Nat Med"},{"key":"2253_CR27","doi-asserted-by":"publisher","first-page":"97671","DOI":"10.18632\/oncotarget.18311","volume":"8","author":"X Zhu","year":"2017","unstructured":"Zhu X, Lang J. Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer. Oncotarget. 2017;8:97671\u201382.","journal-title":"Oncotarget"},{"key":"2253_CR28","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","volume":"8","author":"HD Dong","year":"2002","unstructured":"Dong HD, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7\u2013H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med. 2002;8:793\u2013800.","journal-title":"Nat Med"},{"key":"2253_CR29","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1097\/CJI.0b013e3181fad2b0","volume":"33","author":"T Inozume","year":"2010","unstructured":"Inozume T, Hanada KI, Wang QJ, Ahmadzadeh M, Wunderlich JR, Rosenberg SA, et al. Selection of CD8+PD-1+ Lymphocytes in Fresh Human Melanomas Enriches for Tumor-reactive T Cells. J ImmunoTher. 2010;33:956\u201364.","journal-title":"J ImmunoTher"},{"key":"2253_CR30","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1084\/jem.20160801","volume":"214","author":"VR Juneja","year":"2017","unstructured":"Juneja VR, McGuire KA, Manguso RT, LaFleur MW, Collins N, Haining WN, et al. PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. J Exp Med. 2017;214:895\u2013904.","journal-title":"J Exp Med"},{"key":"2253_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173240","volume":"881","author":"XB Yu","year":"2020","unstructured":"Yu XB, Gao RL, Li YQ, Zeng CW. Regulation of PD-1 in T cells for cancer immunotherapy. Eur J Pharmacol. 2020;881: 173240.","journal-title":"Eur J Pharmacol"},{"key":"2253_CR32","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/s41590-020-0620-x","volume":"21","author":"B Diskin","year":"2020","unstructured":"Diskin B, Adam S, Cassini MF, Sanchez G, Liria M, Aykut B, et al. PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer. Nat Immunol. 2020;21:442\u201354.","journal-title":"Nat Immunol"},{"key":"2253_CR33","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1159\/000430980","volume":"134","author":"M Grzywnowicz","year":"2015","unstructured":"Grzywnowicz M, Karczmarczyk A, Skorka K, Zajac M, Zaleska J, Chocholska S, et al. Expression of programmed death 1 ligand in different compartments of chronic lymphocytic leukemia. Acta Haematol. 2015;134:255\u201362.","journal-title":"Acta Haematol"},{"key":"2253_CR34","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1186\/s12885-017-3578-9","volume":"17","author":"Z Liu","year":"2017","unstructured":"Liu Z, Qi L, Li Y, Zhao X, Sun B. VEGFR2 regulates endothelial differentiation of colon cancer cells. BMC Cancer. 2017;17:593.","journal-title":"BMC Cancer"},{"key":"2253_CR35","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/35025220","volume":"407","author":"P Carmeliet","year":"2000","unstructured":"Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249\u201357.","journal-title":"Nature"},{"issue":"Suppl 3","key":"2253_CR36","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1159\/000088478","volume":"69","author":"P Carmeliet","year":"2005","unstructured":"Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology. 2005;69(Suppl 3):4\u201310.","journal-title":"Oncology"},{"key":"2253_CR37","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","volume":"176","author":"RS Apte","year":"2019","unstructured":"Apte RS, Chen DS, Ferrara N. VEGF in signaling and disease: Beyond discovery and development. Cell. 2019;176:1248\u201364.","journal-title":"Cell"},{"key":"2253_CR38","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nature10144","volume":"473","author":"P Carmeliet","year":"2011","unstructured":"Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473:298\u2013307.","journal-title":"Nature"},{"key":"2253_CR39","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/cdd.2009.152","volume":"17","author":"Z Zhang","year":"2010","unstructured":"Zhang Z, Neiva KG, Lingen MW, Ellis LM, N\u00f6r JE. VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2. Cell Death Differ. 2010;17:499\u2013512.","journal-title":"Cell Death Differ"},{"key":"2253_CR40","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/nrm1911","volume":"7","author":"AK Olsson","year":"2006","unstructured":"Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol. 2006;7:359\u201371.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2253_CR41","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1080\/15384047.2015.1121344","volume":"17","author":"Z Chen","year":"2016","unstructured":"Chen Z, Xie W, Acheampong DO, Xu M, He H, Yang M, et al. A human IgG-like bispecific antibody co-targeting epidermal growth factor receptor and the vascular endothelial growth factor receptor 2 for enhanced antitumor activity. Cancer Biol Ther. 2016;17:139\u201350.","journal-title":"Cancer Biol Ther"},{"key":"2253_CR42","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.1038\/s41467-018-05812-2","volume":"9","author":"HJ Zhou","year":"2018","unstructured":"Zhou HJ, Xu Z, Wang Z, Zhang H, Zhuang ZW, Simons M, et al. SUMOylation of VEGFR2 regulates its intracellular trafficking and pathological angiogenesis. Nat Commun. 2018;9:3303.","journal-title":"Nat Commun"},{"key":"2253_CR43","doi-asserted-by":"publisher","first-page":"583","DOI":"10.2174\/1871520617666171020124916","volume":"18","author":"G Niu","year":"2018","unstructured":"Niu G, Sun L, Pei Y, Wang D. Oleanolic acid inhibits colorectal cancer angiogenesis by blocking the VEGFR2 signaling pathway. Anticancer Agents Med Chem. 2018;18:583\u201390.","journal-title":"Anticancer Agents Med Chem"},{"key":"2253_CR44","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1097\/CAD.0000000000000896","volume":"31","author":"M Wang","year":"2020","unstructured":"Wang M, Jiang X. SUMOylation of vascular endothelial growth factor receptor 2 inhibits the proliferation, migration, and angiogenesis signaling pathway in non-small cell lung cancer. Anticancer Drugs. 2020;31:492\u20139.","journal-title":"Anticancer Drugs"},{"key":"2253_CR45","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1002\/ijc.32180","volume":"145","author":"G Wang","year":"2019","unstructured":"Wang G, Sun M, Jiang Y, Zhang T, Sun W, Wang H, et al. Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma. Int J Cancer. 2019;145:979\u201393.","journal-title":"Int J Cancer"},{"key":"2253_CR46","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1093\/bioinformatics\/btp120","volume":"25","author":"C Trapnell","year":"2009","unstructured":"Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics. 2009;25:1105\u201311.","journal-title":"Bioinformatics"},{"key":"2253_CR47","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:139\u201340.","journal-title":"Bioinformatics"},{"key":"2253_CR48","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.1016\/j.ddtec.2010.03.002","volume":"7","author":"J Kolkman","year":"2010","unstructured":"Kolkman J, Law D. Nanobodies - from llamas to therapeutic proteins. Drug Discov Today Technol. 2010;7:e95\u2013146.","journal-title":"Drug Discov Today Technol"},{"key":"2253_CR49","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1097\/CAD.0000000000001640","volume":"35","author":"ZY Zhu","year":"2024","unstructured":"Zhu ZY, Nie XY, Deng LX, Ding J, Chen JP, Zhu JY, et al. Regulation of cervical cancer via G15-mediated inhibition of G protein-coupled estrogen receptor. Anti-Cancer Drug. 2024;35:817\u201329.","journal-title":"Anti-Cancer Drug"},{"key":"2253_CR50","doi-asserted-by":"crossref","unstructured":"Yabuki Y, Mitsuhashi A, Ogino H, Yoshida A, Nguyen NT, Yoneda H, et al. Hypoxia-inducible factor-targeting therapy augmented the sensitivity to programmed death ligand-1 blockade by enhancing interferon-\u03b3-induced chemokines in tumor cells. Int J Cancer. 2024. Online ahead of print","DOI":"10.1002\/ijc.35301"},{"key":"2253_CR51","doi-asserted-by":"publisher","first-page":"820","DOI":"10.2174\/1568009623666230804161607","volume":"24","author":"J Li","year":"2024","unstructured":"Li J, Wang XH, Li ZL, Li MZ, Zheng XL, Zheng DX, et al. SULF1 Activates the VEGFR2\/PI3K\/AKT Pathway to Promote the Development of Cervical Cancer. Curr Cancer Drug Tar. 2024;24:820\u201334.","journal-title":"Curr Cancer Drug Tar"},{"key":"2253_CR52","doi-asserted-by":"publisher","first-page":"6655","DOI":"10.1021\/acssensors.4c02246","volume":"9","author":"LN Zhu","year":"2024","unstructured":"Zhu LN, Zhang YX, Ding JN, Xin WJ, Fan GC, Song ZL, et al. Intelligent DNA Nanosystem for Broad-Spectrum Oncological Typing and Therapy. Acs Sensors. 2024;9:6655\u201366.","journal-title":"Acs Sensors"},{"key":"2253_CR53","doi-asserted-by":"publisher","first-page":"9760","DOI":"10.1002\/cam4.5696","volume":"12","author":"M Sato","year":"2023","unstructured":"Sato M, Maishi N, Hida Y, Yanagawa-Matsuda A, Alam MT, Sakakibara-Konishi J, et al. Angiogenic inhibitor pre-administration improves the therapeutic effects of immunotherapy. Cancer Med-Us. 2023;12:9760\u201373.","journal-title":"Cancer Med-Us"},{"key":"2253_CR54","doi-asserted-by":"publisher","first-page":"eabe9124","DOI":"10.1126\/science.abe9124","volume":"372","author":"P Zareie","year":"2021","unstructured":"Zareie P, Szeto C, Farenc C, Gunasinghe SD, Kolawole EM, Nguyen A, et al. Canonical T cell receptor docking on peptide-MHC is essential for T cell signaling. Science. 2021;372:eabe9124.","journal-title":"Science."},{"key":"2253_CR55","doi-asserted-by":"publisher","first-page":"3969","DOI":"10.4049\/jimmunol.154.8.3969","volume":"154","author":"RA Kurt","year":"1995","unstructured":"Kurt RA, Park JA, Panelli MC, Schluter SF, Marchalonis JJ, Carolus B, et al. T-lymphocytes infiltrating sites of tumor rejection and progression display identical V-beta usage but different cytotoxic activities. J Immunol. 1995;154:3969\u201374.","journal-title":"J Immunol."},{"key":"2253_CR56","doi-asserted-by":"publisher","first-page":"eaas9103","DOI":"10.1126\/sciimmunol.aas9103","volume":"3","author":"JP Snook","year":"2018","unstructured":"Snook JP, Kim C, Williams MA. TCR signal strength controls the differentiation of CD4+ effector and memory T cells. Sci Immunol. 2018;3:eaas9103.","journal-title":"Sci Immunol."},{"key":"2253_CR57","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S0966-3274(02)00052-7","volume":"10","author":"CC Baan","year":"2002","unstructured":"Baan CC, van Riemsdijk-Overbeeke IC, Boelaars-van Haperen MJAM, IJzermans JMN, Weimar W. Inhibition of the IL-15 pathway in anti-CD25 mAb treated renal allograft recipients. Transpl Immunol. 2002;10:81\u20137.","journal-title":"Transpl Immunol."},{"key":"2253_CR58","doi-asserted-by":"publisher","first-page":"113694","DOI":"10.1016\/j.ejmech.2021.113694","volume":"224","author":"M Piotrowska","year":"2021","unstructured":"Piotrowska M, Spodzieja M, Kuncewicz K, Rodziewicz-Motowid\u0142o S, Orlikowska M. CD160 protein as a new therapeutic target in a battle against autoimmune, infectious and lifestyle diseases. Analysis of the structure, interactions and functions. Eur J Med Chem. 2021;224:113694.","journal-title":"Eur J Med Chem"},{"key":"2253_CR59","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s12094-020-02422-7","volume":"23","author":"Q Guo","year":"2021","unstructured":"Guo Q, Xu J, Huang Z, Yao Q, Chen F, Liu H, et al. ADMA mediates gastric cancer cell migration and invasion via Wnt\/\u03b2-catenin signaling pathway. Clin Transl Oncol. 2021;23:325\u201334.","journal-title":"Clin Transl Oncol"},{"key":"2253_CR60","doi-asserted-by":"publisher","first-page":"4835","DOI":"10.1038\/s41467-020-18570-x","volume":"11","author":"Q Peng","year":"2020","unstructured":"Peng Q, Qiu X, Zhang Z, Zhang S, Zhang Y, Liang Y, et al. PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade. Nat Commun. 2020;11:4835.","journal-title":"Nat Commun"},{"key":"2253_CR61","doi-asserted-by":"publisher","first-page":"eaba8627","DOI":"10.1126\/scisignal.aba8627","volume":"13","author":"A Hervieu","year":"2020","unstructured":"Hervieu A, Heuss SF, Zhang C, Barrow-McGee R, Joffre C, Menard L, et al. A PI3K- and GTPase-independent Rac1-mTOR mechanism mediates MET-driven anchorage-independent cell growth but not migration. Sci Signal. 2020;13:eaba8627.","journal-title":"Sci Signal."},{"key":"2253_CR62","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.3390\/ijms19113595","volume":"19","author":"F Papaccio","year":"2018","unstructured":"Papaccio F, Della Corte CM, Viscardi G, Di Liello R, Esposito G, Sparano F, et al. HGF\/MET and the immune system: Relevance for cancer immunotherapy. Int J Mol Sci. 2018;19:3595.","journal-title":"Int J Mol Sci"},{"key":"2253_CR63","doi-asserted-by":"publisher","first-page":"11942","DOI":"10.1038\/ncomms11942","volume":"7","author":"R Barrow-McGee","year":"2016","unstructured":"Barrow-McGee R, Kishi N, Joffre C, Menard L, Hervieu A, Bakhouche BA, et al. Beta 1-integrin-c-Met cooperation reveals an inside-in survival signalling on autophagy-related endomembranes. Nat Commun. 2016;7:11942.","journal-title":"Nat Commun"},{"key":"2253_CR64","doi-asserted-by":"publisher","first-page":"e002451","DOI":"10.1136\/jitc-2021-002451","volume":"9","author":"QW Wang","year":"2021","unstructured":"Wang QW, Sun LH, Zhang Y, Wang Z, Zhao Z, Wang ZL, et al. MET overexpression contributes to STAT4-PD-L1 signaling activation associated with tumor-associated, macrophages-mediated immunosuppression in primary glioblastomas. J ImmunoTher Cancer. 2021;9:e002451.","journal-title":"J ImmunoTher Cancer"},{"key":"2253_CR65","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1158\/2159-8290.CD-20-1500","volume":"11","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Yang QF, Zeng XY, Wang MX, Dong S, Yang B, et al. MET amplification attenuates lung tumor response to immunotherapy by inhibiting STING. Cancer Discov. 2021;11:2726\u201337.","journal-title":"Cancer Discov"},{"key":"2253_CR66","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.matbio.2024.09.002","volume":"134","author":"O Doppelt-Flikshtain","year":"2024","unstructured":"Doppelt-Flikshtain O, Asbi T, Younis A, Ginesin O, Cohen Z, Tamari T, et al. Inhibition of osteosarcoma metastasis in vivo by targeted downregulation of MMP1 and MMP9. Matrix Biol. 2024;134:48\u201358.","journal-title":"Matrix Biol"},{"key":"2253_CR67","doi-asserted-by":"publisher","first-page":"22242","DOI":"10.1002\/jcp.28792","volume":"234","author":"S Mummidi","year":"2019","unstructured":"Mummidi S, Das NA, Carpenter AJ, Yoshida T, Yariswamy M, Mostany R, et al. RECK suppresses interleukin-17\/TRAF3IP2-mediated MMP-13 activation and human aortic smooth muscle cell migration and proliferation. J Cell Physiol. 2019;234:22242\u201359.","journal-title":"J Cell Physiol"},{"key":"2253_CR68","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.exer.2017.04.007","volume":"160","author":"M Wolf","year":"2017","unstructured":"Wolf M, Maltseva I, Clay SM, Pan P, Gajjala A, Chan MF. Effects of MMP12 on cell motility and inflammation during corneal epithelial repair. Exp Eye Res. 2017;160:11\u201320.","journal-title":"Exp Eye Res"},{"key":"2253_CR69","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/B978-0-12-800178-3.00006-3","volume":"312","author":"JA McDonald","year":"2014","unstructured":"McDonald JA. Canonical and noncanonical roles of Par-1\/MARK kinases in cell migration. Int Rev Cell Mol Biol. 2014;312:169\u201399.","journal-title":"Int Rev Cell Mol Biol"},{"key":"2253_CR70","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.gdata.2015.08.011","volume":"6","author":"EA Marshall","year":"2015","unstructured":"Marshall EA, Ng KW, Anderson C, Hubaux R, Thu KL, Lam WL, et al. Gene expression analysis of microtubule affinity-regulating kinase 2 in non-small cell lung cancer. Genom Data. 2015;6:145\u20138.","journal-title":"Genom Data"},{"key":"2253_CR71","doi-asserted-by":"publisher","first-page":"9240","DOI":"10.3390\/ijms22179240","volume":"22","author":"Y Tahira","year":"2021","unstructured":"Tahira Y, Sakai K, Sato H, Imamura R, Matsumoto K. Dimer interface in natural variant NK1 is dispensable for HGF-dependent MET receptor activation. Int J Mol Sci. 2021;22:9240.","journal-title":"Int J Mol Sci"},{"key":"2253_CR72","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1158\/0008-5472.CAN-13-2420","volume":"74","author":"G Cheng","year":"2014","unstructured":"Cheng G, Sun X, Wang J, Xiao G, Wang X, Fan X, et al. HIC1 silencing in triple-negative breast cancer drives progression through misregulation of LCN2. Cancer Res. 2014;74:862\u201372.","journal-title":"Cancer Res"},{"key":"2253_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216484","volume":"581","author":"S Cerdido","year":"2024","unstructured":"Cerdido S, Abrisqueta M, Sanchez-Beltran J, Lambertos A, Castejon-Grinan M, Munoz C, et al. MGRN1 depletion promotes intercellular adhesion in melanoma by upregulation of E-cadherin and inhibition of CDC42. Cancer Lett. 2024;581: 216484.","journal-title":"Cancer Lett"},{"key":"2253_CR74","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1158\/0008-5472.CAN-23-0539","volume":"83","author":"Z Li","year":"2023","unstructured":"Li Z, Li T, Yates ME, Wu Y, Ferber A, Chen L, et al. The estrogene database reveals diverse temporal, context-dependent, and bidirectional estrogen receptor regulomes in breast cancer. Cancer Res. 2023;83:2656\u201374.","journal-title":"Cancer Res"},{"key":"2253_CR75","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12943-024-02022-x","volume":"23","author":"T Redmer","year":"2024","unstructured":"Redmer T, Raigel M, Sternberg C, Ziegler R, Probst C, Lindner D, et al. JUN mediates the senescence associated secretory phenotype and immune cell recruitment to prevent prostate cancer progression. Mol Cancer. 2024;23:114.","journal-title":"Mol Cancer"},{"key":"2253_CR76","doi-asserted-by":"publisher","first-page":"7324","DOI":"10.1074\/jbc.M111.306936","volume":"287","author":"CB Lai","year":"2012","unstructured":"Lai CB, Mager DL. Role of runt-related transcription factor 3 (RUNX3) in transcription regulation of natural cytotoxicity receptor 1 (NCR1\/NKp46), an activating natural killer (NK) cell receptor. J Biol Chem. 2012;287:7324\u201334.","journal-title":"J Biol Chem"},{"key":"2253_CR77","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3390\/vaccines8020166","volume":"8","author":"F Riccardo","year":"2020","unstructured":"Riccardo F, Barutello G, Petito A, Tarone L, Conti L, Arigoni M, et al. Immunization against ROS1 by DNA electroporation impairs K-Ras-driven lung adenocarcinomas. Vaccines (Basel). 2020;8:166.","journal-title":"Vaccines (Basel)"},{"key":"2253_CR78","doi-asserted-by":"publisher","first-page":"71574","DOI":"10.18632\/oncotarget.17776","volume":"8","author":"S Jahid","year":"2017","unstructured":"Jahid S, Sun J, Gelincik O, Blecua P, Edelmann W, Kucherlapati R, et al. Inhibition of colorectal cancer genomic copy number alterations and chromosomal fragile site tumor suppressor FHIT and WWOX deletions by DNA mismatch repair. Oncotarget. 2017;8:71574\u201386.","journal-title":"Oncotarget"},{"key":"2253_CR79","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12943-018-0928-4","volume":"18","author":"X Jiang","year":"2019","unstructured":"Jiang X, Wang J, Deng X, Xiong F, Ge J, Xiang B, et al. Role of the tumor microenvironment in PD-L1\/PD-1-mediated tumor immune escape. Mol Cancer. 2019;18:10.","journal-title":"Mol Cancer"},{"key":"2253_CR80","first-page":"17","volume":"350","author":"HT Jin","year":"2011","unstructured":"Jin HT, Ahmed R, Okazaki T. Role of PD-1 in regulating T-cell immunity. Curr Top Microbiol Immunol. 2011;350:17\u201337.","journal-title":"Curr Top Microbiol Immunol"},{"key":"2253_CR81","doi-asserted-by":"publisher","first-page":"16824","DOI":"10.1002\/jcp.28358","volume":"234","author":"A Salmaninejad","year":"2019","unstructured":"Salmaninejad A, Valilou SF, Shabgah AG, Aslani S, Alimardani M, Pasdar A, et al. PD-1\/PD-L1 pathway: Basic biology and role in cancer immunotherapy. J Cell Physiol. 2019;234:16824\u201337.","journal-title":"J Cell Physiol"},{"key":"2253_CR82","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1038\/s41467-021-22965-9","volume":"12","author":"KT Li","year":"2021","unstructured":"Li KT, Yuan Z, Lyu JT, Ahn E, Davis SJ, Ahmed R, et al. PD-1 suppresses TCR-CD8 cooperativity during T-cell antigen recognition. Nat Commun. 2021;12:2746.","journal-title":"Nat Commun"},{"key":"2253_CR83","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s42003-020-0845-0","volume":"3","author":"N Patsoukis","year":"2020","unstructured":"Patsoukis N, Duke-Cohan JS, Chaudhri A, Aksoylar HI, Wang Q, Council A, et al. Interaction of SHP-2 SH2 domains with PD-1 ITSM induces PD-1 dimerization and SHP-2 activation. Commun Biol. 2020;3:128.","journal-title":"Commun Biol"},{"key":"2253_CR84","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3389\/fphar.2017.00561","volume":"8","author":"HO Alsaab","year":"2017","unstructured":"Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: Mechanism, combinations, and clinical outcome. Front Pharmacol. 2017;8:561.","journal-title":"Front Pharmacol"},{"key":"2253_CR85","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1158\/0008-5472.CAN-10-2217","volume":"71","author":"Y Cao","year":"2011","unstructured":"Cao Y, Zhang L, Kamimura Y, Ritprajak P, Hashiguchi M, Hirose S, et al. B7\u2013H1 overexpression regulates epithelial-mesenchymal transition and accelerates carcinogenesis in skin. Cancer Res. 2011;71:1235\u201343.","journal-title":"Cancer Res"},{"key":"2253_CR86","doi-asserted-by":"publisher","first-page":"328rv4","DOI":"10.1126\/scitranslmed.aad7118","volume":"8","author":"W Zou","year":"2016","unstructured":"Zou W, Wolchok JD, Chen L. PD-L1 (B7\u2013H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016;8:328rv4.","journal-title":"Sci Transl Med."},{"key":"2253_CR87","doi-asserted-by":"publisher","first-page":"663","DOI":"10.3390\/cancers13040663","volume":"13","author":"Y Yuan","year":"2021","unstructured":"Yuan Y, Adam A, Zhao C, Chen H. Recent advancements in the mechanisms underlying resistance to PD-1\/PD-L1 blockade immunotherapy. Cancers (Basel). 2021;13:663.","journal-title":"Cancers (Basel)"},{"key":"2253_CR88","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/nm0603-669","volume":"9","author":"N Ferrara","year":"2003","unstructured":"Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669\u201376.","journal-title":"Nat Med"},{"key":"2253_CR89","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1172\/JCI65385","volume":"123","author":"S Chatterjee","year":"2013","unstructured":"Chatterjee S, Heukamp LC, Siobal M, Sch\u00f6ttle J, Wieczorek C, Peifer M, et al. Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. J Clin Invest. 2013;123:1732\u201340.","journal-title":"J Clin Invest"},{"key":"2253_CR90","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.apsb.2020.09.008","volume":"11","author":"P Shang","year":"2021","unstructured":"Shang P, Gao R, Zhu Y, Zhang X, Wang Y, Guo M, et al. VEGFR2-targeted antibody fused with IFN \u03b1 mut regulates the tumor microenvironment of colorectal cancer and exhibits potent anti-tumor and anti-metastasis activity. Acta Pharm Sin B. 2021;11:420\u201333.","journal-title":"Acta Pharm Sin B"},{"key":"2253_CR91","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/annonc\/mdv615","volume":"27","author":"J Chen","year":"2016","unstructured":"Chen J, Jiang CC, Jin L, Zhang XD. Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Ann Oncol. 2016;27:409\u201316.","journal-title":"Ann Oncol"},{"key":"2253_CR92","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1358332","volume":"6","author":"DJ Pinato","year":"2017","unstructured":"Pinato DJ, Black JR, Trousil S, Dina RE, Trivedi P, Mauri FA, et al. Programmed cell death ligands expression in phaeochromocytomas and paragangliomas: Relationship with the hypoxic response, immune evasion and malignant behavior. Oncoimmunology. 2017;6: e1358332.","journal-title":"Oncoimmunology"},{"key":"2253_CR93","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1136\/jclinpath-2017-204853","volume":"71","author":"A Kythreotou","year":"2018","unstructured":"Kythreotou A, Siddique A, Mauri FA, Bower M, Pinato DJ. PD-L1. J Clin Pathol. 2018;71:189\u201394.","journal-title":"J Clin Pathol"},{"key":"2253_CR94","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jconrel.2016.11.015","volume":"244","author":"F Danhier","year":"2016","unstructured":"Danhier F. To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine? J Control Release. 2016;244:108\u201321.","journal-title":"J Control Release"},{"key":"2253_CR95","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11886-019-1121-0","volume":"21","author":"P Menna","year":"2019","unstructured":"Menna P, Minotti G, Salvatorelli E. Cardiotoxicity of targeted cancer drugs: concerns, \u201cThe cart before the horse,\u201d and lessons from trastuzumab. Curr Cardiol Rep. 2019;21:33.","journal-title":"Curr Cardiol Rep"},{"key":"2253_CR96","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1007\/s10529-016-2160-x","volume":"38","author":"R Bakhtiar","year":"2016","unstructured":"Bakhtiar R. Antibody drug conjugates. Biotechnol Lett. 2016;38:1655\u201364.","journal-title":"Biotechnol Lett"},{"key":"2253_CR97","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.2217\/imt-2021-0068","volume":"13","author":"O Abdel-Rahman","year":"2021","unstructured":"Abdel-Rahman O. Association between PD-L1 inhibitor, tumor site and adverse events of potential immune etiology within the US FDA adverse event reporting system. Immunotherapy-Uk. 2021;13:1407\u201317.","journal-title":"Immunotherapy-Uk"},{"key":"2253_CR98","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.apsb.2021.09.010","volume":"12","author":"ZW Fan","year":"2022","unstructured":"Fan ZW, Wu CY, Chen MM, Jiang YY, Wu YY, Mao RF, et al. The generation of PD-L1 and PD-L2 in cancer cells: From nuclear chromatin reorganization to extracellular presentation. Acta Pharm Sin B. 2022;12:1041\u201353.","journal-title":"Acta Pharm Sin B"},{"key":"2253_CR99","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1007\/s10637-018-0689-3","volume":"37","author":"W Hou","year":"2019","unstructured":"Hou W, Yuan Q, Yuan X, Wang Y, Mo W, Wang H, et al. A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer. Invest New Drugs. 2019;37:876\u201389.","journal-title":"Invest New Drugs"},{"key":"2253_CR100","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1377874","volume":"7","author":"SL Harwood","year":"2017","unstructured":"Harwood SL, Alvarez-Cienfuegos A, Nu\u00f1ez-Prado N, Compte M, Hern\u00e1ndez-P\u00e9rez S, Merino N, et al. ATTACK, a novel bispecific T cell-recruiting antibody with trivalent EGFR binding and monovalent CD3 binding for cancer immunotherapy. Oncoimmunology. 2017;7: e1377874.","journal-title":"Oncoimmunology"},{"key":"2253_CR101","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s10549-023-06866-7","volume":"198","author":"JL Zhao","year":"2023","unstructured":"Zhao JL, Wu Y, Xiao T, Cheng C, Zhang T, Gao ZY, et al. A specific anti-cyclin D1 intrabody represses breast cancer cell proliferation by interrupting the cyclin D1-CDK4 interaction. Breast Cancer Res Tr. 2023;198:555\u201368.","journal-title":"Breast Cancer Res Tr"},{"key":"2253_CR102","doi-asserted-by":"publisher","first-page":"11227","DOI":"10.1038\/s41598-019-47600-y","volume":"9","author":"L Pastushok","year":"2019","unstructured":"Pastushok L, Fu YP, Lin L, Luo Y, DeCoteau JF, Lee K, et al. A Novel Cell-Penetrating Antibody Fragment Inhibits the DNA Repair Protein RAD51. Sci Rep-Uk. 2019;9:11227.","journal-title":"Sci Rep-Uk"},{"key":"2253_CR103","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.3390\/pharmaceutics15102402","volume":"15","author":"DT Abdeldaim","year":"2023","unstructured":"Abdeldaim DT, Schindowski K. Fc-Engineered Therapeutic Antibodies: Recent Advances and Future Directions. Pharmaceutics. 2023;15:2402.","journal-title":"Pharmaceutics"},{"key":"2253_CR104","doi-asserted-by":"publisher","first-page":"3387","DOI":"10.3390\/ijms24043387","volume":"24","author":"MY Xu","year":"2023","unstructured":"Xu MY, Bi JH, Liang B, Wang XY, Mo R, Feng N, et al. PEGylation Prolongs the Half-Life of Equine Anti-SARS-CoV-2 Specific F(ab\u2019)2. Int J of Mol Sci. 2023;24:3387.","journal-title":"Int J of Mol Sci"},{"key":"2253_CR105","doi-asserted-by":"publisher","first-page":"e1800647","DOI":"10.1002\/biot.201800647","volume":"14","author":"FY Zhou","year":"2019","unstructured":"Zhou FY, Kroetsch A, Nguyen VP, Huang X, Ogoke O, Parashurama N, et al. High-Affinity Antibody Detection with a Bivalent Circularized Peptide Containing Antibody-Binding Domains. Biotechnol J. 2019;14:e1800647.","journal-title":"Biotechnol J"},{"key":"2253_CR106","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.jconrel.2024.11.061","volume":"377","author":"I Alradwan","year":"2025","unstructured":"Alradwan I, Zhi P, Zhang T, Lip H, Zetrini A, He CS, et al. Nanoparticulate drug combination inhibits DNA damage repair and PD-L1 expression in BRCA-mutant and wild type triple-negative breast cancer. J Control Release. 2025;377:661\u201374.","journal-title":"J Control Release"},{"key":"2253_CR107","doi-asserted-by":"publisher","first-page":"104025","DOI":"10.1016\/j.pdpdt.2024.104025","volume":"46","author":"F Akbarzadeh","year":"2024","unstructured":"Akbarzadeh F, Khoshgard K. Enhancement of the effect of novel targeted 5-aminolevulinic acid conjugated bismuth oxide nanoparticles-based photodynamic therapy by simultaneous radiotherapy on KB cells. Photodiagn Photodyn. 2024;46:104025.","journal-title":"Photodiagn Photodyn"},{"issue":"Pt B","key":"2253_CR108","doi-asserted-by":"publisher","first-page":"125004","DOI":"10.1016\/j.ijpharm.2024.125004","volume":"667","author":"X Wang","year":"2024","unstructured":"Wang X, Jing ZQ, Huang XB, Liu XY, Zhang YJ, Wang ZJ, et al. PD-L1 antibody conjugated dihydrotanshinone I-loaded polymeric nanoparticle for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death. Int J Pharmaceut. 2024;667(Pt B):125004.","journal-title":"Int J Pharmaceut"},{"key":"2253_CR109","doi-asserted-by":"crossref","unstructured":"Schmidt A, Oberle N, Weiss EM, Vobis D, Frischbutter S, Baumgrass R, et al. Human regulatory T Cells rapidly suppress T Cell receptor-induced Ca2+, NF-\u03baB, and NFAT signaling in conventional T Cells.\u00a0Sci Signaling. 2011;4:ra90.","DOI":"10.1126\/scisignal.2002179"},{"key":"2253_CR110","doi-asserted-by":"publisher","first-page":"13827","DOI":"10.1038\/srep13827","volume":"5","author":"Y Tu","year":"2015","unstructured":"Tu Y, Liu L, Zhao D, Liu Y, Ma X, Fan Y, et al. Overexpression of miRNA-497 inhibits tumor angiogenesis by targeting VEGFR2. Sci Rep. 2015;5:13827.","journal-title":"Sci Rep"},{"key":"2253_CR111","first-page":"1235","volume":"39","author":"B Lu","year":"2018","unstructured":"Lu B, Liu GL, Yu F, Li WJ, Xiang XX, Xiao HZ. MicroRNA-16\/VEGFR2\/p38\/NF-\u03baB signaling pathway regulates cell growth of human pituitary neoplasms. Oncol Rep. 2018;39:1235\u201344.","journal-title":"Oncol Rep"},{"key":"2253_CR112","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/nature12108","volume":"497","author":"H Dvinge","year":"2013","unstructured":"Dvinge H, Git A, Gr\u00e4f S, Salmon-Divon M, Curtis C, Sottoriva A, et al. The shaping and functional consequences of the microRNA landscape in breast cancer. Nature. 2013;497:378\u201382.","journal-title":"Nature"},{"key":"2253_CR113","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12943-019-1112-1","volume":"19","author":"L Zhang","year":"2020","unstructured":"Zhang L, Li YD, Wang QC, Chen Z, Li XY, Wu ZX, et al. The PI3K subunits, P110\u03b1 and P110\u03b2 are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer. Mol Cancer. 2020;19:10.","journal-title":"Mol Cancer"},{"key":"2253_CR114","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s11010-024-04946-w","volume":"480","author":"CF Zhang","year":"2025","unstructured":"Zhang CF, Wang K, Tao JH, Zheng CJ, Zhai LZ. MYC-dependent MiR-7-5p regulated apoptosis and autophagy in diffuse large B cell lymphoma by targeting AMBRA1. Mol Cell Biochem. 2025;480:191\u2013202.","journal-title":"Mol Cell Biochem"},{"key":"2253_CR115","doi-asserted-by":"publisher","first-page":"110390","DOI":"10.1016\/j.intimp.2023.110390","volume":"120","author":"S Zhao","year":"2023","unstructured":"Zhao S, Liu Y, Wang J, Wen Y, Wu BT, Yang DJ, et al. ADSCs increase the autophagy of chondrocytes through decreasing miR-7\u20135p in Osteoarthritis rats by targeting ATG4A. Int Immunopharmacol. 2023;120:110390.","journal-title":"Int Immunopharmacol"},{"key":"2253_CR116","doi-asserted-by":"publisher","first-page":"109073","DOI":"10.1016\/j.thromres.2024.109073","volume":"241","author":"M Sletten","year":"2024","unstructured":"Sletten M, Skogstrom KB, Lind SM, Tinholt M, Stavik B, Rayner S, et al. Elevated TFPI is a prognostic factor in hepatocellular carcinoma: Putative role of miR-7\u20135p and miR-1236\u20133p. Thromb Res. 2024;241:109073.","journal-title":"Thromb Res"},{"key":"2253_CR117","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.3390\/cancers13051027","volume":"13","author":"N Mohan","year":"2021","unstructured":"Mohan N, Luo X, Shen Y, Olson Z, Agrawal A, Endo Y, et al. A novel bispecific antibody targeting EGFR and VEGFR2 is effective against triple negative breast cancer via multiple mechanisms of action. Cancers. 2021;13:1027.","journal-title":"Cancers"},{"key":"2253_CR118","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2021.112685","volume":"405","author":"K Barzaman","year":"2021","unstructured":"Barzaman K, Samadi M, Moradi-Kalbolandi S, Majidzadeh AK, Salehi M, Jalili N, et al. Development of a recombinant anti-VEGFR2-EPCAM bispecific antibody to improve antiangiogenic efficiency. Exp Cell Res. 2021;405:112685.","journal-title":"Exp Cell Res"},{"key":"2253_CR119","doi-asserted-by":"publisher","first-page":"216181","DOI":"10.1016\/j.canlet.2023.216181","volume":"563","author":"RK Lin","year":"2023","unstructured":"Lin RK, Zhang L, Ye BW, Wang YA, Li YD, Jason H, et al. A multi-functional nano-system combining PI3K-110\u03b1\/\u03b2 inhibitor overcomes P-glycoprotein mediated MDR and improves anti-cancer efficiency. Cancer Lett. 2023;563:216181.","journal-title":"Cancer Lett"},{"key":"2253_CR120","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4161\/cam.5.2.14374","volume":"5","author":"SY Kim","year":"2011","unstructured":"Kim SY, Yasuda S, Tanaka H, Yamagata K, Kim H. Non-clustered protocadherin Cell Adh Migr. 2011;5:97\u2013105.","journal-title":"Non-clustered protocadherin Cell Adh Migr"},{"key":"2253_CR121","doi-asserted-by":"publisher","first-page":"4409","DOI":"10.1038\/onc.2011.609","volume":"31","author":"AR Dallosso","year":"2012","unstructured":"Dallosso AR, \u00d8ster B, Greenhough A, Thorsen K, Curry TJ, Owen C, et al. Long-range epigenetic silencing of chromosome 5q31 protocadherins is involved in early and late stages of colorectal tumorigenesis through modulation of oncogenic pathways. Oncogene. 2012;31:4409\u201319.","journal-title":"Oncogene"},{"key":"2253_CR122","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.302","volume":"5","author":"M Asad","year":"2014","unstructured":"Asad M, Wong MK, Tan TZ, Choolani M, Low J, Mori S, et al. FZD7 drives in vitro aggressiveness in Stem-A subtype of ovarian cancer via regulation of non-canonical Wnt\/PCP pathway. Cell Death Dis. 2014;5: e1346.","journal-title":"Cell Death Dis"},{"key":"2253_CR123","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1158\/1535-7163.MCT-09-0282","volume":"8","author":"Y Wang","year":"2009","unstructured":"Wang Y. Wnt\/Planar cell polarity signaling: a new paradigm for cancer therapy. Mol Cancer Ther. 2009;8:2103\u20139.","journal-title":"Mol Cancer Ther"},{"key":"2253_CR124","doi-asserted-by":"publisher","first-page":"L725","DOI":"10.1152\/ajplung.00346.2014","volume":"309","author":"G Faura Tellez","year":"2015","unstructured":"Faura Tellez G, Vandepoele K, Brouwer U, Koning H, Elderman RM, Hackett TL, et al. Protocadherin-1 binds to SMAD3 and suppresses TGF-\u03b21-induced gene transcription. Am J Physiol Lung Cell Mol Physiol. 2015;309:L725-35.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2253_CR125","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13148-019-0695-0","volume":"11","author":"AF Vega-Benedetti","year":"2019","unstructured":"Vega-Benedetti AF, Loi E, Moi L, Blois S, Fadda A, Antonelli M, et al. Clustered protocadherins methylation alterations in cancer. Clin Epigenetics. 2019;11:100.","journal-title":"Clin Epigenetics"},{"key":"2253_CR126","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1002\/jcb.25194","volume":"116","author":"L Jin","year":"2015","unstructured":"Jin L, Zhu C, Wang X, Li C, Cao C, Yuan J, et al. Urocortin attenuates TGF\u03b21-induced Snail1 and slug expressions: inhibitory role of Smad7 in Smad2\/3 signaling in breast cancer cells. J Cell Biochem. 2015;116:2494\u2013503.","journal-title":"J Cell Biochem"},{"key":"2253_CR127","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1080\/07357900701788106","volume":"26","author":"J Wang","year":"2008","unstructured":"Wang J, Xu Y, Xu Y, Zhu H, Zhang R, Zhang G, et al. Urocortin\u2019s inhibition of tumor growth and angiogenesis in hepatocellular carcinoma via corticotrophin-releasing factor receptor 2. Cancer Invest. 2008;26:359\u201368.","journal-title":"Cancer Invest"},{"key":"2253_CR128","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1677\/joe.1.06726","volume":"190","author":"P Florio","year":"2006","unstructured":"Florio P, De Falco G, Leucci E, Torricelli M, Torres PB, Toti P, et al. Urocortin expression is downregulated in human endometrial carcinoma. J Endocrinol. 2006;190:99\u2013105.","journal-title":"J Endocrinol"},{"key":"2253_CR129","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/cam4.967","volume":"6","author":"GL Owens","year":"2017","unstructured":"Owens GL, Lawrence KM, Jackson TR, Crosbie EJ, Sayan BS, Kitchener HC, et al. Urocortin suppresses endometrial cancer cell migration via CRFR2 and its system components are differentially modulated by estrogen. Cancer Med. 2017;6:408\u201315.","journal-title":"Cancer Med"},{"key":"2253_CR130","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1093\/cvr\/cvt019","volume":"98","author":"SW Han","year":"2013","unstructured":"Han SW, Jung YK, Lee EJ, Park HR, Kim GW, Jeong JH, et al. DICAM inhibits angiogenesis via suppression of AKT and p38 MAP kinase signalling. Cardiovasc Res. 2013;98:73\u201382.","journal-title":"Cardiovasc Res"},{"key":"2253_CR131","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1002\/jbmr.1632","volume":"27","author":"YK Jung","year":"2012","unstructured":"Jung YK, Han SW, Kim GW, Jeong JH, Kim HJ, Choi JY. DICAM inhibits osteoclast differentiation through attenuation of the integrin \u03b1V\u03b23 pathway. J Bone Miner Res. 2012;27:2024\u201334.","journal-title":"J Bone Miner Res"},{"key":"2253_CR132","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109292","volume":"118","author":"ZQ Dong","year":"2019","unstructured":"Dong ZQ, Guo ZY, Xie J. The lncRNA EGFR-AS1 is linked to migration, invasion and apoptosis in glioma cells by targeting miR-133b\/RACK1. Biomed Pharmacother. 2019;118: 109292.","journal-title":"Biomed Pharmacother"},{"key":"2253_CR133","first-page":"1899","volume":"19","author":"S Yuan","year":"2020","unstructured":"Yuan S, Luan X, Chen H, Shi X, Zhang X. Long non-coding RNA EGFR-AS1 sponges micorRNA-381 to upregulate ROCK2 in bladder cancer. Oncol Lett. 2020;19:1899\u2013905.","journal-title":"Oncol Lett"},{"key":"2253_CR134","doi-asserted-by":"publisher","first-page":"175883591985522","DOI":"10.1177\/1758835919855228","volume":"11","author":"H Qi","year":"2019","unstructured":"Qi H, Wang S, Wu J, Yang S, Gray S, Ng CSH, et al. EGFR-AS1\/HIF2A regulates the expression of FOXP3 to impact the cancer stemness of smoking-related non-small cell lung cancer. Ther Adv Med Oncol. 2019;11:1758835919855228.","journal-title":"Ther Adv Med Oncol"},{"key":"2253_CR135","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1038\/s41388-021-01676-x","volume":"40","author":"CC Lin","year":"2021","unstructured":"Lin CC, Yang WH, Lin YT, Tang X, Chen PH, Ding CC, et al. DDR2 upregulation confers ferroptosis susceptibility of recurrent breast tumors through the Hippo pathway. Oncogene. 2021;40:2018\u201334.","journal-title":"Oncogene"},{"key":"2253_CR136","doi-asserted-by":"publisher","first-page":"747","DOI":"10.3233\/CBM-181302","volume":"22","author":"BK Velmurugan","year":"2018","unstructured":"Velmurugan BK, Chang WH, Chung CM, Yeh CM, Lee CH, Yeh KT, et al. DDR2 overexpression in oral squamous cell carcinoma is associated to lymph node metastasis. Cancer Biomark. 2018;22:747\u201353.","journal-title":"Cancer Biomark"},{"key":"2253_CR137","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/ncb2743","volume":"15","author":"K Zhang","year":"2013","unstructured":"Zhang K, Corsa CA, Ponik SM, Prior JL, Piwnica-Worms D, Eliceiri KW, et al. The collagen receptor discoidin domain receptor 2 stabilizes SNAIL1 to facilitate breast cancer metastasis. Nat Cell Biol. 2013;15:677\u201387.","journal-title":"Nat Cell Biol"},{"key":"2253_CR138","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1002\/cbin.11625","volume":"45","author":"QQ Liu","year":"2021","unstructured":"Liu QQ, Liu YW, Xie YK, Zhang JH, Song CX, Wang JZ, et al. Amplification of DDR2 mediates sorafenib resistance through NF-\u03baB\/c-Rel signaling in hepatocellular carcinoma. Cell Biol Int. 2021;45:1906\u201316.","journal-title":"Cell Biol Int"},{"key":"2253_CR139","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13046-015-0218-6","volume":"34","author":"B Xie","year":"2015","unstructured":"Xie B, Lin W, Ye J, Wang X, Zhang B, Xiong S, et al. DDR2 facilitates hepatocellular carcinoma invasion and metastasis via activating ERK signaling and stabilizing SNAIL1. J Exp Clin Cancer Res. 2015;34:101.","journal-title":"J Exp Clin Cancer Res"},{"key":"2253_CR140","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1007\/s10620-016-4116-3","volume":"61","author":"YG Wang","year":"2016","unstructured":"Wang YG, Xu L, Jia RR, Wu Q, Wang T, Wei J, et al. DDR2 induces gastric cancer cell activities via activating mTORC2 signaling and is associated with clinicopathological characteristics of gastric cancer. Dig Dis Sci. 2016;61:2272\u201383.","journal-title":"Dig Dis Sci"},{"key":"2253_CR141","doi-asserted-by":"publisher","first-page":"eaav2437","DOI":"10.1126\/sciadv.aav2437","volume":"5","author":"MM Tu","year":"2019","unstructured":"Tu MM, Lee FYF, Jones RT, Kimball AK, Saravia E, Graziano RF, et al. Targeting DDR2 enhances tumor response to anti-PD-1 immunotherapy. Sci Adv. 2019;5:eaav2437.","journal-title":"Sci Adv"},{"key":"2253_CR142","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1210\/er.2008-0032","volume":"29","author":"GM Gibbs","year":"2008","unstructured":"Gibbs GM, Roelants K, O\u2019Bryan MK. The CAP superfamily: cysteine-rich secretory proteins, antigen 5, and pathogenesis-related 1 proteins\u2013roles in reproduction, cancer, and immune defense. Endocr Rev. 2008;29:865\u201397.","journal-title":"Endocr Rev"},{"key":"2253_CR143","doi-asserted-by":"publisher","first-page":"39553","DOI":"10.1038\/srep39553","volume":"6","author":"GG Hazell","year":"2016","unstructured":"Hazell GG, Peachey AM, Teasdale JE, Sala-Newby GB, Angelini GD, Newby AC, et al. PI16 is a shear stress and inflammation-regulated inhibitor of MMP2. Sci Rep. 2016;6:39553.","journal-title":"Sci Rep"},{"key":"2253_CR144","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1093\/cvr\/cvm102","volume":"78","author":"VW van Hinsbergh","year":"2008","unstructured":"van Hinsbergh VW, Koolwijk P. Endothelial sprouting and angiogenesis: matrix metalloproteinases in the lead. Cardiovasc Res. 2008;78:203\u201312.","journal-title":"Cardiovasc Res"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02253-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-025-02253-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02253-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T07:03:12Z","timestamp":1745046192000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-025-02253-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,19]]},"references-count":144,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2253"],"URL":"https:\/\/doi.org\/10.1186\/s12943-025-02253-6","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,19]]},"assertion":[{"value":"4 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol was approved by the Animal Ethics Committee of Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences. The research strictly adhered to the Declaration of Helsinki, the International Ethical Guidelines for Biomedical Research formulated by the World Health Organization, the Regulations on the Management of Experimental Animals issued by the former State Science and Technology Commission of the People's Republic of China, the Guiding Opinions on the Humane Treatment of Experimental Animals issued by the Ministry of Science and Technology, and the relevant regulations of the National Natural Science Foundation of China.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"119"}}